IRONWOOD PHARMACEUTICALS, INC. Amortization of Debt Issuance Costs
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Amortization of Debt Issuance Costs of $402.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2023-05-04
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2023-03-31 was $402.00K, a 25.14% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2022-12-31 was $400.00K, a 9.30% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2022-09-30 was $399.00K, a 6.34% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2022-06-30 was $516.00K, a 25.24% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2022 was $1.85M, a 10.43% increase from fiscal 2021.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2021 was $1.68M, a 14.77% increase from fiscal 2020.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2020 was $1.46M, a 22.86% increase from fiscal 2019.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2019 was $1.19M.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-03-31 | $402.00K 10-Q · filed 2023-05-04 | $802.00K derived: sum of 2 quarters · filed 2023-05-04 | $1.20M derived: sum of 3 quarters · filed 2023-05-04 | $1.72M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $799.00K derived: sum of 2 quarters · filed 2023-02-16 | $1.31M derived: sum of 3 quarters · filed 2023-02-16 | $1.85M 10-K · filed 2023-02-16 |
| 2022-09-30 | $399.00K 10-Q · filed 2022-11-03 | $915.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.45M 10-Q · filed 2022-11-03 | $1.89M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | $516.00K 10-Q · filed 2022-08-04 | $1.05M 10-Q · filed 2022-08-04 | $1.49M derived: sum of 3 quarters · filed 2023-05-04 | $1.92M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $537.00K 10-Q · filed 2023-05-04 | $978.00K derived: sum of 2 quarters · filed 2023-05-04 | $1.40M derived: sum of 3 quarters · filed 2023-05-04 | $1.82M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $441.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $867.00K derived: sum of 2 quarters · filed 2023-02-16 | $1.28M derived: sum of 3 quarters · filed 2023-02-16 | $1.68M 10-K · filed 2023-02-16 |
| 2021-09-30 | $426.00K 10-Q · filed 2022-11-03 | $838.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.24M 10-Q · filed 2022-11-03 | $1.62M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-06-30 | $412.00K 10-Q · filed 2022-08-04 | $811.00K 10-Q · filed 2022-08-04 | $1.20M derived: sum of 3 quarters · filed 2023-02-16 | $1.57M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-03-31 | $398.00K 10-Q · filed 2022-05-05 | $783.00K derived: sum of 2 quarters · filed 2023-02-16 | $1.16M derived: sum of 3 quarters · filed 2023-02-16 | $1.51M derived: sum of 4 quarters · filed 2023-02-16 |
| 2020-12-31 | $385.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $757.00K derived: sum of 2 quarters · filed 2023-02-16 | $1.12M derived: sum of 3 quarters · filed 2023-02-16 | $1.46M 10-K · filed 2023-02-16 |
| 2020-09-30 | $372.00K 10-Q · filed 2021-11-04 | $732.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.08M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $360.00K 10-Q · filed 2021-08-05 | $705.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $346.00K 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $1.19M 10-K · filed 2022-02-18 | |||
| 2015-09-30 | $137.00K 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |